Company: XAIR
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001641172-25-023243
Chunk: 39

Company: Beyond Air, Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Part I, Item 1
Chunk 39
---
The
depreciation expense related to customer leased devices is included in the cost of revenue in the unaudited condensed consolidated statements
of operations and comprehensive loss.

Capitalized
sales commissions

Sales
commissions related to obtaining LungFit® PH lease agreements are accounted for as initial direct costs and are capitalized and amortized
on a straight-line basis over the lease term. Total capitalized costs for the three months ended June 30, 2025 and June 30, 2024 were
immaterial.

    21

BEYOND
AIR, INC. AND SUBSIDIARIES

NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE
11 SEGMENTS

The
following table summarizes segment financial information by business segment for the three months ended and at June 30, 2025:

 SCHEDULE
OF SEGMENT FINANCIAL INFORMATION BY BUSINESS SEGMENT 

    (in thousands) 
    Beyond
                                                                                                  Air  
    Beyond
                                                                                Cancer  
    NeuroNos   
    Total 
  
    Cash, cash equivalents and marketable securities 
    $3,056  
    $1,777  
    $1,630  
    $6,463 
  
    All other assets 
     21,241  
     398  
     12  
     21,651 
  
    Total assets 
    $24,297  
    $2,175  
    $1,642  
    $28,114 
  
    Total liabilities 
     (16,779) 
     (530) 
     (397) 
     (17,706)
  
    Net assets 
    $7,518  
    $1,645  
    $1,245  
    $10,408 
  
    Non-controlling interest 
    $-  
    $330  
    $151  
    $481 
  
    Capital expenditures 
    $198  
    $-  
    $-  
    $198 

    Revenues 
    $1,760  
    $-  
    $-  
    $1,760 
  
    Cost of revenues 
     (1,604) 
     -  
     -  
     (1,604)
  
    Research and development 
     (2,234) 
     (529